Abstract

The Protocol Review and Monitoring System Clinical Research Review Committee (PRMS-CRC) of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins is responsible for reviewing the scientific merit, priorities, and progress of the clinical research of the Center. Committee approval is required prior to opening a protocol in the Cancer Center. The Committee also has the authority to close protocols that do not demonstrate adequate scientific progress. On average, in 2010 each week the Committee reviewed three new studies, one resubmitted study with PRMS-CRC recommended changes, and two studies for annual progress and performance. The CRC is our Protocol Review and Monitoring System (PRMS).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-49
Application #
8559690
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-08-09
Project End
2017-04-30
Budget Start
2012-08-09
Budget End
2013-04-30
Support Year
49
Fiscal Year
2012
Total Cost
$86,624
Indirect Cost
$33,152

  Institution

Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218

  Publications

Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225

Showing the most recent 10 out of 2393 publications